Joe Wiley

Stories

Karyopharm files for bankruptcy to sell itself to Ayrmid

Leading the acquisition of Karyopharm through Chapter 11

Karyopharm Therapeutics filed for Chapter 11 bankruptcy on November 2, 2026, and agreed to sell itself to Ayrmid Ltd., the Irish parent of cell therapy maker Gamida Cell. Ayrmid is the lead bidder, not the guaranteed buyer: the filing sets up a court-supervised auction where other offers can compete.

Updated 1 hour ago

Notable Quotes

"Complementary portfolios, established commercial capabilities and a shared commitment to addressing significant unmet needs in hematology."

from Karyopharm files for bankruptcy to sell itself to Ayrmid · Updated 1 hour ago

"We look forward to working with the Karyopharm team to realize that potential and continue delivering important therapies to patients in need."

from Karyopharm files for bankruptcy to sell itself to Ayrmid · Updated 1 hour ago